Emerald Raises £1.4 Million for Preventive Health Services
Emerald, a London-based startup specializing in comprehensive in-clinic biomarker testing, has successfully raised £1.4 million in its latest funding round. This round of investment includes contributions from Boost Capital Partners, Sequel, Highgoal Capital, and Innovate UK.
Company Overview
Emerald aims to revolutionize preventive health care by providing in-clinic biomarker testing that integrates GP-reviewed results with past health data. The company offers personalized action plans designed to help individuals understand their health risks earlier and take informed actions with medical support.
Leadership Team
Emerald was co-founded by Alexander Badalyan, who serves as the CEO, Anton Shchipanov, the Chief Technology Officer, and Dan McNally, who fulfills the role of Chief Medical Officer. The team is focused on expanding the reach and capabilities of their health services.
Use of Funds
While specific plans for the newly raised funds were not disclosed, it is expected that Emerald will use this capital to enhance its biomarker testing technology and expand its customer base. The investment will likely support the company's goal of reaching one million members.
Investor Participation
This funding round did not specify a lead investor but included notable contributions from Boost Capital Partners, Sequel, Highgoal Capital, and Innovate UK. These investors are known for supporting innovative health tech solutions and their involvement underscores confidence in Emerald's growth potential.
Emerald's latest funding marks a significant step in its mission to make preventive health care more accessible and effective, allowing individuals to take proactive steps in managing their health.